Aaron P Havas
Overview
Explore the profile of Aaron P Havas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller K, Li B, Pierce-Hoffman H, Patel S, Lei X, Rajesh A, et al.
Nat Commun
. 2025 Mar;
16(1):2229.
PMID: 40044657
Genomic instability and inflammation are distinct hallmarks of aging, but the connection between them is poorly understood. Here we report a mechanism directly linking genomic instability and inflammation in senescent...
2.
Miller K, Li B, Pierce-Hoffman H, Patel S, Lei X, Rajesh A, et al.
bioRxiv
. 2023 Dec;
PMID: 38045344
Genomic instability and inflammation are distinct hallmarks of aging, but the connection between them is poorly understood. Understanding their interrelationship will help unravel new mechanisms and therapeutic targets of aging...
3.
Havas A, Tula-Sanchez A, Steenhoek H, Bhakta A, Wingfield T, Huntley M, et al.
Transl Oncol
. 2023 Oct;
39:101779.
PMID: 37865047
Approved histone deacetylase (HDAC) inhibitors have low efficacy against the most commonly-diagnosed non-Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), but the mechanisms underlying clinical resistance are poorly understood. Using...
4.
Onorati A, Havas A, Lin B, Rajagopal J, Sen P, Adams P, et al.
Mol Cell Biol
. 2022 Sep;
42(10):e0017122.
PMID: 36154662
Cellular senescence is a stable form of cell cycle arrest associated with proinflammatory responses. Senescent cells can be cleared by the immune system as a part of normal tissue homeostasis....
5.
Havas A, Rodrigues K, Bhakta A, Demirjian J, Hahn S, Tran J, et al.
Cancer Biol Ther
. 2016 Oct;
17(12):1240-1252.
PMID: 27791595
Diffuse Large B-cell lymphoma (DLBCL) is an aggressive malignancy that has a 60 percent 5-year survival rate, highlighting a need for new therapeutic approaches. Histone deacetylase inhibitors (HDACi) are novel...
6.
Tula-Sanchez A, Havas A, Alonge P, Klein M, Doctor S, Pinkston W, et al.
Cancer Biol Ther
. 2013 Aug;
14(10):949-61.
PMID: 23982416
Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors...